Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory

Also known as: Refractory B-cell precursor acute lymphoblastic leukemia / Precursor B-lymphoblastic lymphoma/leukemia refractory / Refractory B cell precursor Acute lymphoblastic leukemia / Refractory B-cell precursor Acute Lymphoblastic Anemia / Precursor B-lymphoblastic lymphoma refractory / Precursor B-lymphoblastic lymphoma NOS refractory

Drug	Drug Name	Drug Description
DB09052	Blinatumomab	An antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD).
DB15699	Brexucabtagene autoleucel	A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ζ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma.
DB05889	Inotuzumab ozogamicin	An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
DB13881	Tisagenlecleucel	A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma.

Drug	Drug Name	Target	Type
DB09052	Blinatumomab	B-lymphocyte antigen CD19	target
DB09052	Blinatumomab	T-cell surface glycoprotein CD3 delta chain	target
DB15699	Brexucabtagene autoleucel	B-lymphocyte antigen CD19	target
DB05889	Inotuzumab ozogamicin	P-glycoprotein 1	transporter
DB05889	Inotuzumab ozogamicin	B-cell receptor CD22	target
DB13881	Tisagenlecleucel	B-lymphocyte antigen CD19	target

Drug	Drug Name	Phase	Status	Count
DB13881	Tisagenlecleucel	2	Unknown Status	1